To date, this business segment has been supported with government grant and contract funding from the National Institute of Allergy and Infectious Diseases (NIAID), the Defense Threat Reduction Agency ...

Advancing novel programs for respiratory viruses that pose pandemic threats or risk of serious illness, including SARS CoV2 (ratutrelvir) and influenza (Tivoxavir marboxil, TXM) Prioritization of ratu ...

Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing ...

VANGUARD has selected five companies for up to $200,000 in non-dilutive funding contracts and 10 companies for the 2025 ...

From the editorial, "While a virus may be more fear-inducing, ultra-processed food can prove just as life-shortening, albeit not quite as suddenly. This is not a new threat, of course. " ...

Advancing novel programs for respiratory viruses that pose pandemic threats or risk of serious illness, including SARS CoV2 ...

ALLSCHWIL, Switzerland I August 14, 2025 I Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting ...

The Trump administration’s decision to halt nearly $500 million for mRNA vaccine research has made investors more hesitant to ...

HHS is slashing hundreds of millions in funding for mRNA vaccines and infectious disease treatments, but leaving the door ...

It ain’t what you don’t know that gets you into trouble. It’s what you know for sure that just ain’t so.” Mark Twain’s quip ...

Director Jay Bhattacharya claims the federal government recently canceled millions of dollars’ worth of mRNA research ...

(Reuters) -Vaxart said on Wednesday it received an order to stop work on screening and enrollment for its COVID-19 mid-stage ...